There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on 4D Molecular Therapeutics (FDMT – Research Report) and Biogen (BIIB – Research Report) with bullish sentiments.
4D Molecular Therapeutics (FDMT)
Jefferies analyst Kelly Shi maintained a Buy rating on 4D Molecular Therapeutics today and set a price target of $58.00. The company’s shares closed last Thursday at $31.86, close to its 52-week high of $36.25.
According to TipRanks.com, Shi is a 2-star analyst with an average return of
4D Molecular Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $52.00, a 52.2% upside from current levels. In a report issued on March 27, Leerink Partners also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Biogen (BIIB)
In a report released today, Michael Yee from Jefferies maintained a Buy rating on Biogen, with a price target of $285.00. The company’s shares closed last Thursday at $215.63, close to its 52-week low of $211.02.
According to TipRanks.com, Yee is a 3-star analyst with an average return of
Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $293.41, representing a 35.0% upside. In a report issued on March 27, Truist Financial also assigned a Buy rating to the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FDMT:
- 4D Molecular announce update on regulatory interactions, development for 4D-710
- 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
- 4DMT to Participate in Upcoming Investor Conferences
- 4DMT Reports Full Year 2023 Financial Results and Operational Highlights
- 4D Molecular presents interim data from 4D-310 INGLAXA Phase 1/2 trials
